The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.

"We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves ...

“RSV poses a serious health risk to adults with ... Kennedy Jr. A number lambasted Kennedy and the FDA on social media recently when the regulatory agency approved Moderna’s second ...

(The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe ...

MARYLAND – The US Food and Drug Administration (FDA) on June 12 expanded the use of Moderna’s respiratory syncytial virus (RSV) vaccine to a younger group of adults aged 18 to 59 who are at ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.